Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 618 participants.

Also called NCT04834089

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 618 participants (planned count) (from the registry)
Sponsor
Butantan Institute (from the registry)
Registry
  • NCT NCT04834089
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04834089. Randomized; double masking; primary purpose treatment. Start 2021-05 (anticipated); primary completion 2022-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases
Acronym
SOROCOV
Condition
Immunosuppression
Condition
Cancer
Condition
COVID-19
Condition
Other Complication of Kidney Transplant
Condition
Chemotherapy
Condition
Renal Disease
Condition
Diabetes Mellitus
Condition
Cardiovascular Diseases
Condition
Chronic Obstructive Pulmonary Disease
Intervention (Biological)
AntiSARS-CoV-2 Serum
Intervention (Other)
Placebo
Lead sponsor
Butantan Institute (class: other government)

Record details

Record id
cardio:ct-nct04834089
Content hash
a355ab42dc681c70f1c267b660917396859f7fe6b2d4f8a2fbffdee0f51b6f8a